EWM
IMDX

Executive Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Executive Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2
Closed – – 569
2019
Q2 		$0 Hold
2
– – ﹤0.01% 928
2019
Q1 		$0 Buy
+2
New +$129 ﹤0.01% 901

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.18B AUM 18.43% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return

Executive Wealth Management's IMDX Position: Q3 2019 in Review

Executive Wealth Management sold out of Insight Molecular Diagnostics (IMDX) in Q3 2019, closing a stake of 2 shares.

Executive Wealth Management first reported a position in IMDX in Q1 2019 and held it in 2 quarters. The position peaked at $0 in Q2 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q3 2019.

  • Executive Wealth Management reported no remaining Insight Molecular Diagnostics position as of Q3 2019 after selling out during the quarter.
  • Executive Wealth Management sold 2 Insight Molecular Diagnostics shares in Q3 2019.
  • Executive Wealth Management first reported a position in Insight Molecular Diagnostics in Q1 2019 and held it in 2 quarters.
  • Executive Wealth Management's Insight Molecular Diagnostics position peaked at $0 in Q2 2019.
  • 56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2019.

Based on Executive Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.